Decreased nitric oxide in the exhaled air of patients with systemic sclerosis with pulmonary hypertension.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Thorax

• Publication date

  1997-12-01

• Fields of study

  Medicine, Environmental Science

• Identifiers
  DOI 10.1136/thx.52.12.1051PMID 9516898PMCID PMC1758461
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endothelial and fibroblastic activation in scleroderma. The myth of the "uninvolved skin".

  2010cited by this paper
• Endothelium-derived relaxing factors and the human pulmonary circulation

  2007cited by this paper
• Studies on endothelial cell cytotoxic activity in sera of patients with progressive systemic sclerosis, Raynaud syndrome, rheumatoid arthritis, and systemic lupus erythematosus

  2004cited by this paper
• The effects of scleroderma sera on endothelial cell survival in vitro

  2004cited by this paper
• Nasal contribution to exhaled nitric oxide during exhalation against resistance or during breath holding.

  1997cited by this paper
• Increased production of the potent oxidant peroxynitrite in the lungs of patients with idiopathic pulmonary fibrosis.

  1997cited by this paper
• Increased exhaled nitric oxide in asthma is mainly derived from the lower respiratory tract.

  1996cited by this paper
• Exhaled nitric oxide: a new lung function test.

  1996cited by this paper
• Quantitative analysis of parenchymal and vascular alterations in NO2-induced lung injury in rats.

  1995cited by this paper
• Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension.

  1995cited by this paper
• Low-dose almitrine bismesylate in the treatment of hypoxemia due to chronic obstructive pulmonary disease.

  1994cited by this paper
• Increased nitric oxide in exhaled air of asthmatic patients.

  1994cited by this paper
• Role of Endothelial-Derived Nitric Oxide in Normal and Hypertensive Pulmonary Vasculature

  1994cited by this paper
• Expression of inducible nitric oxide in human lung epithelial cells.

  1994cited by this paper
• Peak expiratory nitric oxide differences in men and women: relation to the menstrual cycle.

  1994cited by this paper
• Endothelial control of the pulmonary circulation in normal and chronically hypoxic rats.

  1993cited by this paper
• Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

  1993cited by this paper
• Measurement of exhaled nitric oxide in man.

  1993cited by this paper
• Lung volumes and forced ventilatory flows

  1993cited by this paper
• Nitric oxide regulates the expression of vasoconstrictors and growth factors by vascular endothelium under both normoxia and hypoxia.

  1993cited by this paper
• Chronic EDRF inhibition and hypoxia: effects on pulmonary circulation and systemic blood pressure.

  1993cited by this paper
• Platelet adhesion to human vascular endothelium is modulated by constitutive and cytokine induced nitric oxide.

  1993cited by this paper
• A new model of progressive pulmonary fibrosis in rats.

  1993cited by this paper
• The L-arginine-nitric oxide pathway.

  1993cited by this paper
• Nitric oxide and lung disease.

  1993cited by this paper
• Standardization of the measurement of transfer factor (diffusing capacity). Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society.

  1993cited by this paper
• Endothelial modulation of pulmonary vascular tone.

  1992cited by this paper
• Studies of the microvascular endothelium in uninvolved skin of patients with systemic sclerosis: direct evidence for a generalized microangiopathy

  1992cited by this paper
• Sequential dermal microvascular and perivascular changes in the development of scleroderma

  1992cited by this paper
• Isolated diffusing capacity reduction in systemic sclerosis.

  1992cited by this paper
• Nitric Oxide Functions as an Inhibitor of Platelet Adhesion Under Flow Conditions

  1992cited by this paper
• SPSS for Windows Base System User''s Guide

  1992cited by this paper
• Tissue-type plasminogen activator and von Willebrand factor plasma levels as markers of endothelial involvement in patients with Raynaud's phenomenon.

  1992cited by this paper
• Assessment of the peak tricuspid regurgitant velocity from the dynamics of retrograde flow.

  1992cited by this paper
• THE L-ARGININE-NITRIC OXIDE PATHWAY

  1992cited by this paper
• Mortality in systemic sclerosis (scleroderma).

  1992cited by this paper
• Cytoprotective function of nitric oxide: inactivation of superoxide radicals produced by human leukocytes.

  1991cited by this paper
• Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia.

  1991cited by this paper
• Release of nitric oxide from human vascular smooth muscle cells.

  1991cited by this paper
• Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro.

  1991cited by this paper
• Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease.

  1991cited by this paper
• Endogenous nitric oxide is present in the exhaled air of rabbits, guinea pigs and humans.

  1991cited by this paper
• Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide.

  1990cited by this paper
• Local venomotor response to intravenous infusion of substance P and glyceryl trinitrate in systemic sclerosis.

  1990cited by this paper
• Evaluation and management of scleroderma lung disease using bronchoalveolar lavage.

  1990cited by this paper
• The pulmonary pathologic manifestations of the CREST syndrome.

  1990cited by this paper
• Evidence for protein oedema, neutrophil influx, and enhanced collagen production in lungs of patients with systemic sclerosis.

  1990cited by this paper
• Lung function testing and AIDS.

  1989cited by this paper
• Inhibition of platelet-derived mitogen release by nitric oxide (EDRF)

  1989cited by this paper
• Pathophysiological effects of endothelial cytotoxic activity derived from sera of patients with progressive systemic sclerosis.

  1988cited by this paper
• Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium.

  1987cited by this paper
• Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis.

  1986cited by this paper
• Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosis.

  1983cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma).

  1980cited by this paper
• Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

  1980cited by this paper
• Pulmonary vascular changes in scleroderma.

  1978cited by this paper
• Arterialized ear lobe blood samples for blood gas tensions.

  1976cited by this paper

• Alveolar and Bronchial Nitric Oxide Parameters in Pre-Capillary Pulmonary Hypertension

  2025cites this paper
• Systemic Sclerosis-Associated Pulmonary Arterial Hypertension: From Bedside to Bench and Back Again

  2024cites this paper
• Fractional nitric oxide measurement in exhaled air (FeNO): perspectives in the management of respiratory diseases

  2023cites this paper
• Outcome of Obstructed Total Anamalous Pulmonary Venous Connection (TAPVC) Repair Patients with Milrinone Versus Milrinone and Inhaled Nitric Oxide (INO): A Prospective Randomized Observational Study

  2023cites this paper
• Novel use of riociguat in infants with severe pulmonary arterial hypertension unable to wean from inhaled nitric oxide

  2022cites this paper
• Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway

  2021cites this paper
• Extended Exhaled Nitric Oxide Analysis in Interstitial Lung Diseases: A Systematic Review

  2020cites this paper
• Riociguat: Clinical research and evolving role in therapy

  2020cites this paper
• Neonatal comorbidities and gasotransmitters.

  2020cites this paper
• The nitric oxide pathway in pulmonary arterial hypertension: pathomechanism, biomarkers and drug targets.

  2020cites this paper
• Endogenous and Inhaled Nitric Oxide for the Treatment of Pulmonary Hypertension

  2019cites this paper
• Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients.

  2019cites this paper
• Fractional Exhaled Nitric Oxide Measurement in Pulmonary Hypertension: A Follow-Up Study

  2018cites this paper
• Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1461 Pulmonary Hypertension and the Nitric Oxide System

  2018cites this paper
• The MAPK‐activator protein‐1 signaling regulates changes in lung tissue of rat exposed to hypobaric hypoxia

  2018cites this paper
• A Brief Overview of Nitric Oxide and Reactive Oxygen Species Signaling in Hypoxia-Induced Pulmonary Hypertension.

  2017influential citation
• The Nitric Oxide Pathway in Pulmonary Vascular Disease.

  2017cites this paper
• Biomarkers in Pulmonary Vascular Disease: Gauging Response to Therapy.

  2017cites this paper
• Exhaled Nitric Oxide in Systemic Sclerosis Lung Disease

  2017cites this paper
• CTTT Pentanucleotide Repeats in Inducible Nitric Oxide Synthase ene Expression in Patients With Pulmonary Arterial Hypertension

  2017cites this paper
• Pulmonary Hypertension Associated With Scleroderma and Connective Tissue Disease: Potential Molecular and Cellular Targets

  2017cites this paper
• Measurement of exhaled nitric oxide concentration in patients with obstructive sleep apnea

  2017cites this paper
• Riociguat: Mode of Action and Clinical Development in Pulmonary Hypertension

  2017cites this paper
• Relationship between Peripheral Arterial Stiffness and Estimated Pulmonary Pressure by Echocardiography in Systemic Sclerosis.

  2017cites this paper
• The role of endothelial cells in the vasculopathy of systemic sclerosis: A systematic review.

  2017cites this paper
• Pentanucleotide Repeats in Inducible Nitric Oxide Synthase Gene Expression in Patients With Pulmonary Arterial Hypertension

  2017cites this paper
• Plasma nitrite/nitrate levels: a new biomarker for pulmonary arterial hypertension?

  2016cites this paper
• Exhaled Nitric Oxide in Pulmonary Arterial Hypertension Associated with Systemic Sclerosis

  2016cites this paper
• Increased alveolar nitric oxide concentration is related to nocturnal oxygen desaturation in obstructive sleep apnoea.

  2015cites this paper
• Increased exhaled nitric oxide precedes lung fibrosis in two murine models of systemic sclerosis

  2015cites this paper
• Application of nitric oxide measurements in clinical conditions beyond asthma

  2015influential citation
• Treatment-related biomarkers in pulmonary hypertension.

  2015cites this paper
• Primary Ciliary Dyskinesia: An Update on New Diagnostic Modalities and Review of the Literature

  2014cites this paper
• Intérêts des explorations fonctionnelles respiratoires et des études des biomarqueurs dans le diagnostic et le suivi évolutif de la pneumopathie interstitielle diffuse dans la sclérodermie systémique

  2014cites this paper
• CCTTT Pentanucleotide Repeats in Inducible Nitric Oxide Synthase Gene Expression in Patients With Pulmonary Arterial Hypertension

  2014cites this paper
• Reduced levels of S-nitrosothiols in plasma of patients with systemic sclerosis and Raynaud's phenomenon

  2014cites this paper
• CCTTT pentanucleotide repeats in inducible nitric oxide synthase gene expression in patients with pulmonary arterial hypertension.

  2014cites this paper
• [Use of pulmonary function tests and biomarkers studies to diagnose and follow-up interstitial lung disease in systemic sclerosis].

  2014cites this paper
• Pulmonary hypertension: novel pathways and emerging therapies inhibitors of cGMP and cAMP metabolism.

  2013cites this paper
• Breath Tests in Respiratory and Critical Care Medicine: From Research to Practice in Current Perspectives

  2013cites this paper
• Oral therapies for pulmonary arterial hypertension: endothelin receptor antagonists and phosphodiesterase-5 inhibitors.

  2013cites this paper
• Nitric oxide deficiency and endothelial dysfunction in pulmonary arterial hypertension.

  2013cites this paper
• Breath biomarkers in diagnosis of pulmonary diseases.

  2012cites this paper
• Tadalafil for the treatment of pulmonary arterial hypertension

  2011cites this paper
• Rôle de l’inflammation alvéolaire dans la survenue et l'aggravation de la pneumopathie interstitielle diffuse au cours de la sclérodermie systémique

  2011cites this paper
• Biomarkers in systemic sclerosis-related pulmonary arterial hypertension.

  2011cites this paper
• Combination therapy for the treatment of pulmonary arterial hypertension

  2011cites this paper
• Diagnosis and Management of Pulmonary Arterial Hypertension

  2011influential citation
• Secondary pulmonary hypertension

  2010cites this paper
• Effect of Oral Arginine Supplementation on Exhaled Nitric Oxide Concentration in Sickle Cell Anemia and Acute Chest Syndrome

  2010cites this paper
• Fractional exhaled nitric oxide in asthma: an update

  2010cites this paper
• Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis.

  2009cites this paper
• Serum and bronchoalveolar lavage fluid nitric oxide levels in diffuse systemic sclerosis

  2009cites this paper
• Vascular Disease in Scleroderma

  2009cites this paper
• Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis.

  2009cites this paper
• Systemic sclerosis at the cellular level: molecular pathways of pathogenesis and its implication on future drug design.

  2009cites this paper
• Inhibition of p38 MAPK reverses hypoxia-induced pulmonary artery endothelial dysfunction.

  2009cites this paper
• Oxidative stress and the pathogenesis of scleroderma: the Murrell’s hypothesis revisited

  2008cites this paper
• Exhaled Nitric Oxide in Patients with Interstitial Lung Disease: A Pilot Study

  2008cites this paper
• Asymmetrical dimethylarginine in systemic sclerosis-related pulmonary arterial hypertension.

  2008cites this paper
• Connective Tissue Disease Associated Pulmonary Hypertension

  2008cites this paper
• Serum nitric oxide metabolites and disease activity in patients with systemic sclerosis

  2008cites this paper
• 3 SYSTEMIC SCLEROSIS Vascular , Pulmonary and Immunological Aspects

  2008cites this paper
• Nitric oxide metabolism and the acute chest syndrome of sickle cell anemia

  2008cites this paper
• Respiratory Ciliary Dysfunction

  2008cites this paper
• Interstitial lung disease in systemic sclerosis

  2007cites this paper
• КЛИНИЧЕСКИЕ ПРОЯВЛЕНИЯ ПОРАЖЕНИЯ ЛЕГКИХ ПРИ СИСТЕМНОЙ СКЛЕРОДЕРМИИ

  2007cites this paper
• The nitric oxide/cGMP signaling pathway in pulmonary hypertension.

  2007cites this paper
• Effects of prostaglandin E1α cyclodestrin treatment on endothelial dysfunction in patients with systemic sclerosis

  2007cites this paper
• Nitric oxide and nursing: a review.

  2007cites this paper
• Effects of prostaglandin E1alpha cyclodextrin [corrected] treatment on endothelial dysfunction in patients with systemic sclerosis.

  2007cites this paper
• Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide

  2007cites this paper
• Title: Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide Short title: Exhaled CANO and scleroderma lung disease

  2007cites this paper
• Exhaled nitric oxide levels in systemic sclerosis with and without pulmonary involvement.

  2007cites this paper
• Matucci-Cerinic Interstitial lung disease in systemic sclerosis

  2007cites this paper
• Abnormal exhaled ethane concentrations in scleroderma

  2006cites this paper
• Biologie et physiologie

  2006cites this paper
• application and interpretation Exhaled nitric oxide measurements: clinical

  2006cites this paper
• Nitric oxide and systemic sclerosis.

  2006cites this paper
• NOS2 polymorphisms associated with the susceptibility to pulmonary arterial hypertension with systemic sclerosis: contribution to the transcriptional activity

  2006cites this paper
• Exhaled nitric oxide measurements: clinical application and interpretation

  2006cites this paper
• A Mathematical Model for the Evolution of Nitric Oxide Concentration in Human Breathing

  2006cites this paper
• Pulmonary Involvement in Systemic Sclerosis

  2006cites this paper
• Sclerosing panniculitis is associated with pulmonary hypertension in systemic sclerosis

  2005cites this paper
• The transport of cationic amino acids in human airway cells: expression of system y+L activity and transepithelial delivery of NOS inhibitors

  2005cites this paper
• Pulmonary Arterial Hypertension in Systemic Sclerosis

  2004cites this paper
• Correlations between Exhaled Nitric Oxide Levels and pH-Metry Data in Asthmatics with Gastro-Oesophageal Reflux

  2004cites this paper
• Pulmonary hypertension in autoimmune rheumatic diseases.

  2004cites this paper
• 31 – Gender-Specific Considerations in Pulmonary Hypertension

  2004cites this paper
• Pulmonary hypertension in chronic obstructive pulmonary disease

  2003cites this paper
• Decreased exhaled nitric oxide in sickle cell disease: Relationship with chronic lung involvement

  2003cites this paper
• Oxygen administration improves the serum level of nitric oxide metabolites in patients with obstructive sleep apnea syndrome.

  2003cites this paper
• Reduced nitric oxide in sinus epithelium of patients with radiologic maxillary sinusitis and sepsis.

  2003cites this paper
• Scleroderma and pulmonary hypertension

  2003cites this paper
• Plasma plasmin-alpha2-plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension.

  2003cites this paper
• Nasal nitric oxide measurements for the screening of primary ciliary dyskinesia

  2003cites this paper
• Sildenafil for pulmonary arterial hypertension: exciting, but protection required.

  2003cites this paper
• Plasma levels of endothelin-1, big endothelin-1 and thromboxane following acute pulmonary air embolism.

  2003cites this paper
• Plasma plasmin–α2‐plasmin inhibitor complex levels are increased in systemic sclerosis patients with pulmonary hypertension

  2003cites this paper
• Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG and arterial blood gases

  2002cites this paper